Cargando…

Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah

Background Differentiated thyroid cancer is a common endocrine cancer; most of it has an indolent course and favorable outcomes, with a subset of patients having the risk of disease recurrence, which can be assessed using the fixed American Thyroid Association (ATA) risk stratification system or the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasim, Mahmod S, Hussein, Ibrahim H, Alidrisi, Haider A, Mansour, Abbas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686578/
https://www.ncbi.nlm.nih.gov/pubmed/38034160
http://dx.doi.org/10.7759/cureus.47990
_version_ 1785151804762226688
author Jasim, Mahmod S
Hussein, Ibrahim H
Alidrisi, Haider A
Mansour, Abbas A
author_facet Jasim, Mahmod S
Hussein, Ibrahim H
Alidrisi, Haider A
Mansour, Abbas A
author_sort Jasim, Mahmod S
collection PubMed
description Background Differentiated thyroid cancer is a common endocrine cancer; most of it has an indolent course and favorable outcomes, with a subset of patients having the risk of disease recurrence, which can be assessed using the fixed American Thyroid Association (ATA) risk stratification system or the dynamic response to therapy risk stratification that can be modified during patients follow-up. Aim The aim of this article is to assess the risk stratification of patients having differentiated thyroid cancer. Methods This is a retrospective cross-sectional study in which we evaluated medical records of 75 patients having differentiated thyroid cancer to assess the baseline ATA risk of recurrence and compared it to the results of dynamic risk stratification in response to therapy at 6-12 months post-surgery and at the last visit. Thyroglobulin level, anti-thyroglobulin antibody, thyroid ultrasound, and cytopathological examination were used to determine dynamic response to therapy and divided subjects into four groups: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR), and indeterminate response (IR). Results At baseline, 55 patients had low risk, 14 patients had intermediate risk, and six patients had high risk. At 6-12 months post-surgery, in the low-risk group, ER, BIR, and IR responses were observed in 56.4%, 5.5%, and 38.2% of patients, respectively, and none of them exhibited SIR. In the intermediate-risk group, ER, BIR, and IR responses were observed in 57.1%, 21.4%, and 21.4% of patients, respectively, and none exhibited SIR. Among the high-risk group, two patients had ER, two patients had BIR, one patient had IR, and one patient had SIR. At the last visit, ER, BIR, and IR were observed in 65.5%, 9.1%, and 25.5% of low-risk patients, respectively, and no patient developed SIR. In the intermediate-risk group, ER, BIR, and IR were observed in 50%, 21.4%, and 28.6% of patients, respectively, and no patients developed SIR. Among the high-risk group, three patients achieved ER, one had BIR, one had IR, and one had SIR. Conclusion Most of the differentiated thyroid cancers in this study are low-risk. Dynamic risk stratification appears to be an effective tool in the follow-up of this population of patients having differentiated thyroid cancer.
format Online
Article
Text
id pubmed-10686578
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106865782023-11-30 Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah Jasim, Mahmod S Hussein, Ibrahim H Alidrisi, Haider A Mansour, Abbas A Cureus Endocrinology/Diabetes/Metabolism Background Differentiated thyroid cancer is a common endocrine cancer; most of it has an indolent course and favorable outcomes, with a subset of patients having the risk of disease recurrence, which can be assessed using the fixed American Thyroid Association (ATA) risk stratification system or the dynamic response to therapy risk stratification that can be modified during patients follow-up. Aim The aim of this article is to assess the risk stratification of patients having differentiated thyroid cancer. Methods This is a retrospective cross-sectional study in which we evaluated medical records of 75 patients having differentiated thyroid cancer to assess the baseline ATA risk of recurrence and compared it to the results of dynamic risk stratification in response to therapy at 6-12 months post-surgery and at the last visit. Thyroglobulin level, anti-thyroglobulin antibody, thyroid ultrasound, and cytopathological examination were used to determine dynamic response to therapy and divided subjects into four groups: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR), and indeterminate response (IR). Results At baseline, 55 patients had low risk, 14 patients had intermediate risk, and six patients had high risk. At 6-12 months post-surgery, in the low-risk group, ER, BIR, and IR responses were observed in 56.4%, 5.5%, and 38.2% of patients, respectively, and none of them exhibited SIR. In the intermediate-risk group, ER, BIR, and IR responses were observed in 57.1%, 21.4%, and 21.4% of patients, respectively, and none exhibited SIR. Among the high-risk group, two patients had ER, two patients had BIR, one patient had IR, and one patient had SIR. At the last visit, ER, BIR, and IR were observed in 65.5%, 9.1%, and 25.5% of low-risk patients, respectively, and no patient developed SIR. In the intermediate-risk group, ER, BIR, and IR were observed in 50%, 21.4%, and 28.6% of patients, respectively, and no patients developed SIR. Among the high-risk group, three patients achieved ER, one had BIR, one had IR, and one had SIR. Conclusion Most of the differentiated thyroid cancers in this study are low-risk. Dynamic risk stratification appears to be an effective tool in the follow-up of this population of patients having differentiated thyroid cancer. Cureus 2023-10-30 /pmc/articles/PMC10686578/ /pubmed/38034160 http://dx.doi.org/10.7759/cureus.47990 Text en Copyright © 2023, Jasim et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Jasim, Mahmod S
Hussein, Ibrahim H
Alidrisi, Haider A
Mansour, Abbas A
Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title_full Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title_fullStr Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title_full_unstemmed Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title_short Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah
title_sort risk stratification of differentiated thyroid cancer: a single-center study in basrah
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686578/
https://www.ncbi.nlm.nih.gov/pubmed/38034160
http://dx.doi.org/10.7759/cureus.47990
work_keys_str_mv AT jasimmahmods riskstratificationofdifferentiatedthyroidcancerasinglecenterstudyinbasrah
AT husseinibrahimh riskstratificationofdifferentiatedthyroidcancerasinglecenterstudyinbasrah
AT alidrisihaidera riskstratificationofdifferentiatedthyroidcancerasinglecenterstudyinbasrah
AT mansourabbasa riskstratificationofdifferentiatedthyroidcancerasinglecenterstudyinbasrah